SF3B1 and intrahepatic cholangiocarcinoma: MDS with ring sideroblasts (MDS-RS) was revised, and the name was changed to MDS with low blasts and SF3B1 mutations (MDS, LB, and SF3B1) by the 2022 WHO and MDS with mutated SF3B1 (MDS-SF3B1) in the ICC.